Patents by Inventor Shau-Ping Lei

Shau-Ping Lei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050196400
    Abstract: Gene expression elements and their use in production of chimeric antibodies with human constant regions and murine variable regions, and mouse human chimeric antibodies having specificity to human tumor cells, methods of their production, and their use.
    Type: Application
    Filed: October 3, 2002
    Publication date: September 8, 2005
    Inventors: Marc Better, Arnold Horwitz, Randy Robinson, Shau-Ping Lei, Changtung Chang
  • Publication number: 20030096343
    Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains.
    Type: Application
    Filed: January 9, 2002
    Publication date: May 22, 2003
    Applicant: XOMA Technology Ltd.
    Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
  • Patent number: 6461824
    Abstract: The invention is directed to chimeric immunoglobulins that recognize a human tumor antigen bound by antibody, ING-2, ING-3, ING-4 or KM10, the production of such chimeric immunoglobulins, and their use.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 8, 2002
    Assignee: Xoma Technology Ltd.
    Inventors: Marc D. Better, Arnold H. Horwitz, Randy R. Robinson, Shau-Ping Lei, Changtung Paul Chang
  • Patent number: 6204023
    Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts tansformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 20, 2001
    Assignee: XOMA Ltd.
    Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
  • Patent number: 5846818
    Abstract: The invention is directed to the pectate lyase B secretion signal and its use to express operably linked sequences in bacterial hosts.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 8, 1998
    Assignee: XOMA Corporation
    Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horowitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
  • Patent number: 5843685
    Abstract: The invention is directed to a chimeric immunoglobulin that recognizes the human tumor antigen bound by antibody ING-1, its production, and use.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: Xoma Corporation
    Inventors: Marc D. Better, Arnold H. Horwitz, Randy R. Robinson, Shau-Ping Lei, Changtung Paul Chang
  • Patent number: 5698435
    Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 16, 1997
    Assignee: Xoma Corporation
    Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
  • Patent number: 5698417
    Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 16, 1997
    Assignee: Xoma Corporation
    Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
  • Patent number: 5693493
    Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: December 2, 1997
    Assignee: Xoma Corporation
    Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
  • Patent number: 5618920
    Abstract: The invention relates to the secretion of heavy chain immunoglobulin fragments and light chain immunoglobulins from prokaryotic hosts using a prokaryotic secretion signal peptide wherein the heavy chain fragments and light chains are capable of associating to form an antigen binding antibody fragment.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: April 8, 1997
    Assignee: Xoma Corporation
    Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
  • Patent number: 5595898
    Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains.The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable-of binding antigens on target cancer cells.
    Type: Grant
    Filed: August 18, 1994
    Date of Patent: January 21, 1997
    Assignee: Xoma Corporation
    Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
  • Patent number: 5576184
    Abstract: Gene expression elements and their use in production of chimeric antibodies with human constant regions and murine variable regions, and mouse human chimeric antibodies having specificity to human tumor cells, methods of their production, and their use.
    Type: Grant
    Filed: December 27, 1994
    Date of Patent: November 19, 1996
    Assignee: Xoma Corporation
    Inventors: Marc D. Better, Arnold H. Horwitz, Randy R. Robinson, Shau-Ping Lei, Changtung P. Chang
  • Patent number: 5576195
    Abstract: The invention relates to DNA coding for a pectate lyase signal peptide which has been inserted into plasmids to create secretion vectors which are capable of producing a chosen protein by directing transport across the bacterial membrane. The secretion vectors have been used to secrete extracellular thaumatin and extracellular antibody fragments. The proteins produced by these vectors have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: November 19, 1996
    Assignee: Xoma Corporation
    Inventors: Randy R. Robinson, Marc Better, Shau-Ping Lei, Gary L. Wilcox
  • Patent number: 5418157
    Abstract: Genetically engineered E. coli carry vectors containing inserts that code for Clostridium histolyticum collagenase. These inserts code for: (a) a form of collagenase having a molecular weight of about 68,000 daltons in the essential absence of larger forms of collagenase; (b) the 68 kd form of collagenase and a fusion polypeptide consisting of the collagenase protein fused to at least a portion of the .beta.-galactosidase protein of E. coli or (3) the 68 kd form of collagenase and polypeptides of molecular weight of from above about 68,000 daltons to about 100,000 daltons and having the enzymatic activity of C. histolyticum collagenase as indicated by digestion of .sup.3 H-acetylated collagen and by specific inhibition by 1,10-phenanthroline plus EDTA. The collagenase genes in the transformed E. coli are expressed efficiently in the transformed cells to yield enzymatically active and immunologically cross-reactive collagenase.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: May 23, 1995
    Inventors: Hun-Chi Lin, Shau-Ping Lei
  • Patent number: 5416202
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) such as gelonin and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: December 9, 1992
    Date of Patent: May 16, 1995
    Assignee: XOMA Corporation
    Inventors: Susan L. Bernhard, Marc D. Better, Steve F. Carroll, Julie A. Lane, Shau-Ping Lei
  • Patent number: 5177017
    Abstract: Genetically engineered E. coli carry vectors containing inserts that code for Clostridium histolyticum collagenase. These inserts code for: (a) a form of collagenase having a molecular weight of about 68,000 daltons in the essential absence of larger forms of collagenase; (b) the 68 kd form of collagenase and a fusion polypeptide consisting of the collagenase protein fused to at least a portion of the .beta.-galactosidase protein of E. coli; or (3) the 68 kd form of collagenase and polypeptides of molecular weight of from above about 68,000 daltons to about 100,000 daltons and having the enzymatic activity of C. histolyticum collagenase as indicated by digestion of .sup.3 H-acetylated collagen and by specific inhibition by 1,10-phenanthroline plus EDTA. The collagenase genes in the transformed E. coli are expressed efficiently in the transformed cells to yield enzymatically active and immunologically cross-reactive collagenase.
    Type: Grant
    Filed: March 22, 1990
    Date of Patent: January 5, 1993
    Assignee: Trigen, Inc.
    Inventors: Hun-Chi Lin, Shau-Ping Lei